RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Syndax Pharmaceuticals Stock

Syndax Pharmaceuticals ROE 2024

Syndax Pharmaceuticals ROE

-0.38

Ticker

SNDX

ISIN

US87164F1057

WKN

A2AFL6

In 2024, Syndax Pharmaceuticals's return on equity (ROE) was -0.38, a 18.27% increase from the -0.32 ROE in the previous year.

Syndax Pharmaceuticals Aktienanalyse

What does Syndax Pharmaceuticals do?

Syndax Pharmaceuticals Inc. is a biotechnology company based in Waltham, Massachusetts that focuses on the development of novel therapeutics for cancer and immune disorders. The company was founded in 2005 by Arlene Morris and has been listed on NASDAQ since 2014. Business model and product pipeline: Syndax develops small molecules that are capable of modulating epigenetic changes in cells. This approach is based on the understanding that cancer cells often have genetic alterations that result in changes in gene expression. By modulating such epigenetic changes, cancer cells can function normally again, which can help stop or inhibit the growth of cancer cells. The company's product pipeline includes several drugs that are being developed in various stages of clinical research. One of the most advanced programs is E2112, an orally administered drug targeting breast cancer. The drug is currently in Phase III studies that are investigating the efficacy and safety of the drug in combination with other standard therapies. Another promising program is SNDX-6352, an anti-CSF-1 receptor antibody being developed for the treatment of various types of cancer, including certain solid tumors and hematologic malignancies. The drug has been successfully tested in Phase Ib studies, and the company is currently planning to evaluate it in further clinical trials. In addition to cancer research, Syndax is also working on the development of therapeutics for various inflammatory and immunologic diseases. The company is working on a program for the treatment of idiopathic pulmonary fibrosis and also a program for the treatment of thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. In addition to internally developed drugs, the company is collaborating with other biotechnology and pharmaceutical companies to explore innovative treatment options for other diseases. The company has entered into a partnership with Japanese company Kyowa Hakko Kirin Co. Ltd. to develop and market the SNDX-6352 program. Current developments: Syndax has recently experienced strong growth and is investing significantly in research and development to expand its pipeline and expand its drugs. The company recently completed a financing round that raised $80 million to advance its development projects. A key milestone for the company was the appointment of Briggs W. Morrison as CEO in 2020. Morrison, an experienced pharmaceutical manager, was previously the Chief Executive Officer and President of Syndax until 2016. He is now returning to the company and leading efforts to develop innovative therapeutics. Morrison has previously worked at Pfizer and AstraZeneca, bringing valuable experience in the development and marketing of new drugs. Summary: Syndax Pharmaceuticals Inc. is a biotechnology company that focuses on the development of drugs for cancer and inflammatory diseases. The company has a promising product pipeline that includes several therapeutics in various stages of development, including E2112 and SNDX-6352. Syndax recently completed a strong financing round and plans to continue its research and development efforts to discover and develop new innovative therapeutics. Syndax Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Syndax Pharmaceuticals's Return on Equity (ROE)

Syndax Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Syndax Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Syndax Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Syndax Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Syndax Pharmaceuticals stock

What is the ROE (Return on Equity) of Syndax Pharmaceuticals this year?

The ROE of Syndax Pharmaceuticals this year is -0.38 undefined.

How has the Return on Equity (ROE) of Syndax Pharmaceuticals developed compared to the previous year?

The ROE of Syndax Pharmaceuticals has increased by 18.27% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Syndax Pharmaceuticals?

A high ROE indicates that Syndax Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Syndax Pharmaceuticals?

A low ROE can indicate that Syndax Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Syndax Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Syndax Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Syndax Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Syndax Pharmaceuticals?

Some factors that can influence Syndax Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Syndax Pharmaceuticals pay?

Over the past 12 months, Syndax Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Syndax Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Syndax Pharmaceuticals?

The current dividend yield of Syndax Pharmaceuticals is .

When does Syndax Pharmaceuticals pay dividends?

Syndax Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Syndax Pharmaceuticals?

Syndax Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Syndax Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Syndax Pharmaceuticals located?

Syndax Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Syndax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Syndax Pharmaceuticals from 12/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/20/2024.

When did Syndax Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/20/2024.

What was the dividend of Syndax Pharmaceuticals in the year 2023?

In the year 2023, Syndax Pharmaceuticals distributed 0 USD as dividends.

In which currency does Syndax Pharmaceuticals pay out the dividend?

The dividends of Syndax Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Syndax Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Syndax Pharmaceuticals

Our stock analysis for Syndax Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Syndax Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.